The authors describe the clinical case of a naive patient with chronic hepatitis HBV-related (CHB) HBeAg negative, treated with Telbivudine (LdT) 600mg/day. After six months of treatment, as well as it determines rapid, profound and sustained suppression of HBV replication, LdT induced a progressive decline of HBsAg serum level and HBsAg loss, probably through an immune modulator effect. Recent studies have indicated the possible action of LdT on the immune system and specifically it would be able to stimulate Th1 lymphocyte subpopulation by increasing their cytokines production, thus playing a major role in cleaning the HBV infection. This aspect appears to be of much interest in clinical practice, because on-treatment HBsAg rapid decline >1 log10 IU/mL during the first year of treatment is highly predictive for future HBsAg clearance and CHB resolution.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Feasibility of implementing viral hepatitis services into a correctional service facility in Cape Town, South Africa.
Int J Drug Policy
January 2025
Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Main Road, Observatory, Cape Town, South Africa. Electronic address:
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are estimated to be of the most prevalent infectious diseases in correctional settings worldwide. However, viral hepatitis services have not been routinely integrated into South African correctional facilities. We aimed to assess prevalence of HBV infection and HCV infection among people accessing HIV services and assess the feasibility of viral hepatitis service integration in a South African correctional centre.
View Article and Find Full Text PDFDifferential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment.
J Transl Med
October 2024
Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Several studies have reported that combination antiretroviral therapy (cART) enhances the hepatitis B surface antigen (HBsAg) clearance rate in Human Immunodeficiency Virus-1/Hepatitis B Virus (HIV/HBV) coinfected patients, yet the associated immunological characteristics remain unclear.
Methods: Global and specific immune phenotypic profiles were examined in 48 patients with HIV/HBV coinfection before cART and at 1-year, and 3-year after cART using flow cytometry. In addition, 61 patients with HBV monoinfection were included for comparison.
Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.
Antiviral Res
November 2024
Arbutus Biopharma Inc., Warminster, PA, USA.
HBV capsid assembly modulators (CAMs) target the core protein and inhibit pregenomic RNA encapsidation and viral replication. HBV CAMs also interfere with cccDNA formation during de novo infection, which in turn suppresses transcription and production of HBV antigens. In this report, we describe the antiviral activities of AB-836, a potent and highly selective HBV CAM.
View Article and Find Full Text PDFRisk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment.
Front Cell Infect Microbiol
August 2024
Out-patient Department, Hospital of Beijing Information Science and Technology University, Beijing, China.
Article Synopsis
- About 20% of patients being treated for chronic hepatitis B experience low-level viraemia (LLV), leading to inflammation, fibrosis progression, and higher cancer risk.
- In a study of 1,653 patients treated with entecavir, factors like HBeAg positivity, high HBV DNA levels, and liver cirrhosis were found to be significantly linked to the development of LLV.
- The findings suggest that monitoring high HBV DNA/HBsAg levels, low platelet counts, and liver health is crucial for identifying patients at risk for LLV during treatment.
A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative.
Hepatology
July 2024
Department of Infectious Diseases, Peking Uinversity First Hospital, Beijing, China.
Article Synopsis
- - The study investigates the effects of ASC22 (a PD-1 antibody) on patients with chronic hepatitis B who are already virally suppressed using nucleos(t)ide analogs, aiming to find a potential cure for HBV by targeting the PD-1 pathway.
- - In a phase IIb trial involving 149 patients, those receiving 1.0 mg/kg ASC22 experienced significant declines in HBsAg levels compared to the placebo group, with 30% achieving HBsAg loss among those with lower baseline levels.
- - The treatment was found to be safe and well-tolerated, with mostly mild adverse events reported, indicating ASC22 has potential as a therapeutic option for chronic hepatitis B infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!